Biogen (BIIB) Research & Development (2009 - 2026)

Biogen has reported Research & Development for 18 years, with the latest figure at $529.6 million in Q2 2026.

• On a quarterly basis, Research & Development rose 32.73% year-over-year to $529.6 million in Q2 2026; TTM through Jun 2026 was $2.0 billion, a 8.13% increase from a year earlier, with the FY2025 full-year figure at $1.8 billion, down 10.19% from the prior year.
• Research & Development was $529.6 million for Q2 2026 at Biogen, down from $539.0 million in the prior quarter.
• The five-year high for Research & Development was $736.3 million in Q3 2023, with the low at $75.0 million in Q4 2023.
• Average Research & Development over 5 years is $501.4 million, with a median of $522.4 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Research & Development tumbled 87.53% in 2023, then surged 584.4% in 2024.
• Over 5 years, Research & Development stood at $601.6 million in 2022, then sank by 87.53% to $75.0 million in 2023, then soared by 584.4% to $513.3 million in 2024, then fell by 0.76% to $509.4 million in 2025, then increased by 3.97% to $529.6 million in 2026.
• The last three Research & Development figures came in at $529.6 million (Q2 2026), $539.0 million (Q1 2026), and $509.4 million (Q4 2025), per Business Quant data.